Sara V. F.
- Country
- Spain
- Department
- Department of Hematology
Research Overview
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
- A Study of Q702 in Patients with Relapsed or Refractory Chronic Graft-versus-Host Disease
- Phase I/IIa Study of Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ectopically Expressing CXCR4 and IL-10 in Patients with Steroid- or Ruxolitinib-Refractory Acute GVHD
Data & Insights
Has run more than one trial at 22 of 90 partner sites.
Specializations
Hematologic Oncology
This clinical investigator specializes in treating B-cell Acute Lymphoblastic Leukemia, with particular emphasis on addressing cases that have become resistant to conventional treatments.
- Relapsed and Refractory Leukemia Management
- Advanced Cell Therapy Applications
- CD19-Directed Therapy Resistance
The investigator's work focuses on developing innovative therapeutic approaches for patients who have exhausted standard treatment options.
Transplantation Medicine
The investigator concentrates on improving outcomes in allogeneic hematopoietic cell transplantation, particularly for patients with hematologic malignancies.
- Transplant Complication Prevention
- Microbiome-Based Interventions
- Post-Transplant Survival Optimization
Their research explores novel approaches to enhance transplant success rates through microbiome modulation.
Therapeutic Innovation
The investigator advances the field through exploration of novel therapeutic modalities in hematologic disorders.
- Oral Microbiotherapy Development
- Cell-Based Treatment Strategies
- Clinical Safety Assessment
Their work integrates cutting-edge therapeutic approaches with established treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.